Saniona AB (SANION.ST) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Sweden · ISIN SE0005794617

Price
11.45 SEK
Market cap
1.51 bn SEK
P/E (2025)
5.32
P/S (2025)
3.49
Dividend yield
0.00 %
Net margin
65.53 %
Return on equity (ROE)
44.82 %
Return on assets (ROA)
41.88 %

Saniona AB financials

Fiscal year20242025
Revenue334.67 m SEK434.40 m SEK
Gross profit329.58 m SEK286.37 m SEK
Operating income241.89 m SEK274.72 m SEK
EBIT244.24 m SEK307.73 m SEK
Net income188.71 m SEK284.67 m SEK
Diluted EPS – continuing operations1.76 SEK2.15 SEK

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; SAN2668, a therapy for severe pediatric epilepsies, including developmental epileptic encephalopathies; and SAN2465, a negative allosteric modulator to treat major depressive disorder. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. The company was founded in 2011 and is headquartered in Glostrup, Denmark.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.